Amylyx Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amylyx Pharmaceuticals (AMLX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$28Upside to Avg. PT+1.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$55→$57
Aug 19, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$30→$42
Aug 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$40→$55
Aug 19, 2026	Baird	Joel Beatty	PT Raise	Outperform	$28→$52
Aug 18, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$34→$55
Aug 17, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$24→$30
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$20→$26
Jul 20, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$21→$24
Jun 25, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$30→$40
Apr 28, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$19→$21
Mar 25, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$34
Mar 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$25→$30
Mar 4, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$28→$34
Mar 3, 2026	Stifel	James Condulis	Initiate	Buy	$21
Feb 20, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$15→$19
Feb 10, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$20→$28
Nov 7, 2025	HC Wainwright & Co.	Andrew Fein	PT Raise	Buy	$16→$20
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$12→$20
Oct 16, 2025	Baird	Joel Beatty	PT Raise	Outperform	$10→$19
Oct 3, 2025	B of A Securities	Geoff Meacham	PT Raise	Buy	$14→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.

Benzinga Newsdesk

Amylyx Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

People Also Watch

People Also Watch

Amylyx Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PROMizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PROBaird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PROHC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PROMizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30